A detailed history of Handelsbanken Fonder Ab transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 13,800 shares of CLDX stock, worth $372,738. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,800
Previous 11,200 23.21%
Holding current value
$372,738
Previous $415,000 13.01%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$32.06 - $44.56 $83,356 - $115,856
2,600 Added 23.21%
13,800 $469,000
Q2 2024

Aug 05, 2024

BUY
$32.76 - $42.56 $101,556 - $131,936
3,100 Added 38.27%
11,200 $415,000
Q4 2023

Feb 01, 2024

BUY
$22.61 - $40.65 $183,141 - $329,265
8,100 New
8,100 $321,000
Q4 2022

Feb 07, 2023

SELL
$27.78 - $45.38 $86,118 - $140,678
-3,100 Reduced 34.83%
5,800 $259,000
Q4 2021

Feb 08, 2022

BUY
$35.68 - $56.27 $317,552 - $500,803
8,900 New
8,900 $344,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.26B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.